Viewing Study NCT00669461


Ignite Creation Date: 2025-12-24 @ 11:50 AM
Ignite Modification Date: 2025-12-24 @ 11:50 AM
Study NCT ID: NCT00669461
Status: TERMINATED
Last Update Posted: 2016-12-30
First Post: 2008-04-28
Is Possible Gene Therapy: False
Has Adverse Events: True

Brief Title: Lubiprostone as a Treatment for Constipation in Parkinson's Disease
Sponsor: University of Arkansas
Organization:

Study Overview

Official Title: Lubiprostone as a Treatment for Constipation in Parkinson's Disease
Status: TERMINATED
Status Verified Date: 2016-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Lack of recruitment
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Delayed colonic transient time secondary to a multi-degenerative process is the most likely cause of constipation in idiopathic PD. Since lubiprostone demonstrated its ability to accelerate colonic transit time in healthy volunteers in addition to activating the chloride channels in the intestinal cells, it has the potential to improve constipation in patients with PD with no subsequent adverse events on the control of the neurological manifestation of PD. So we hypothesize the following:

1. Lubiprostone will improve ratings on the Bristol stool form scale (BSFS) in patients with PD induced constipation compared to baseline.(primary)
2. Lubiprostone will increase the number of spontaneous bowel movements (SBM) per week, compared to baseline. (secondary)
3. Lubiprostone will improve health related quality of life in subjects with PD induced constipation. ( secondary)
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
78055 None None View
FWA00001119 None None View